COMP <GO>
NBP vs OGI // EV/EBITDA & P/E VALUATION
NovaBridge Biosciences (NASDAQ) VS. Organigram Global Inc. (NASDAQ) • 15-METRIC TALLY: NBP 1
— OGI 1
■ METRIC PARITY
LAST: $1.20 (-1.24%) • MKT CAP: $139.6M
valuation
—
LAST: $0.93 (-2.85%) • MKT CAP: $135.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBP VS. OGI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBP | OGI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.8 | 49.6 | -16.81 | OGI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $139.6M | $135.4M | $4.2M | NBP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBP REV | OGI REV | NBP GROSS % | OGI GROSS % | NBP FCF | OGI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | — | — |
| FY 2024 | $0 | — | — | — | — | — |
| FY 2023 | $632.0K | — | — | — | -$183.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBP // BETA —
OGI // BETA —